Combined intraocular and systemic rituximab for ocular lymphoproliferative disorder with extranodal marginal zone lymphoma-type morphology after heart transplant.
Bata, Bashar M
Combined intraocular and systemic rituximab for ocular lymphoproliferative disorder with extranodal marginal zone lymphoma-type morphology after heart transplant. [electronic resource] - Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 04 2018 - 159-161 p. digital
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
1528-3933
10.1016/j.jaapos.2017.10.016 doi
Antineoplastic Agents, Immunological--therapeutic use
Child
Heart Transplantation
Humans
Immunosuppressive Agents--therapeutic use
Injections, Intraocular
Iris Neoplasms--drug therapy
Lymphoma, B-Cell, Marginal Zone--drug therapy
Lymphoproliferative Disorders--drug therapy
Male
Postoperative Complications--drug therapy
Rituximab--therapeutic use
Combined intraocular and systemic rituximab for ocular lymphoproliferative disorder with extranodal marginal zone lymphoma-type morphology after heart transplant. [electronic resource] - Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus 04 2018 - 159-161 p. digital
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
1528-3933
10.1016/j.jaapos.2017.10.016 doi
Antineoplastic Agents, Immunological--therapeutic use
Child
Heart Transplantation
Humans
Immunosuppressive Agents--therapeutic use
Injections, Intraocular
Iris Neoplasms--drug therapy
Lymphoma, B-Cell, Marginal Zone--drug therapy
Lymphoproliferative Disorders--drug therapy
Male
Postoperative Complications--drug therapy
Rituximab--therapeutic use